P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE

• M-C Vekemans,
• M Delforge,
• S Anguille,
• J Depaus,
• N Meuleman,
• A Van de Velde,
• I Vande Broek,
• D Strens,
• S Van Hoorenbeeck,
• EJ Moorkens,
• J Diels,
• F Ghilotti,
• S Dalhuisen,
• S Vandervennet

Affiliations

M-C Vekemans

1 Cliniques Universitaires Saint-Luc, Brussels (BE)

M Delforge

2 Universitaire Ziekenhuizen Leuven, Leuven (BE)

S Anguille

3 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (BE)

J Depaus

5 Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir (BE)

N Meuleman

6 Institut Jules Bordet, Université Libre de Bruxelles, Brussels (BE)

A Van de Velde

4 Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem (BE)

I Vande Broek

8 AZ Nikolaas, Haematology, Sint-Niklaas (BE)

D Strens

9 Realidad bvba, Grimbergen (BE)

S Van Hoorenbeeck

10 Janssen-Cilag NV, Beerse (BE)

EJ Moorkens

10 Janssen-Cilag NV, Beerse (BE)

J Diels

11 Janssen Pharmaceutica NV, Beerse (BE)

F Ghilotti

12 Janssen-Cilag SpA, Cologno Monzese (IT)

S Dalhuisen

13 Janssen-Cilag BV, Breda (NL)

S Vandervennet

10 Janssen-Cilag NV, Beerse (BE)